|
23 Companies |
|
18 Products |
|
18 Products |
|
25 Mechanisms of Action |
|
0 Trials |
|
307 News |
|
| «1234567» |
- ceftriaxone / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: PHANTASi: Prehospital Antibiotics Against Sepsis Trial (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=2200, Recruiting, Sponsor: VU University Medical Center
Not yet recruiting --> Recruiting | Initiation date: Mar 2014 --> Jun 2014 | Trial primary completion date: Mar 2016 --> Jun 2016
- Trial primary completion date: Phase I STEBVax in Healthy Adults (clinicaltrials.gov) - Jul 18, 2014
P1, N=29, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting | Initiation date: Mar 2014 --> Jun 2014 | Trial primary completion date: Mar 2016 --> Jun 2016 Trial primary completion date: Mar 2014 --> Mar 2015
- esmolol / Generic mfg.
Clinical: Echocardiographic and Arterial Pressure Waveform Changes After Reducing Heart Rate With Esmolol in Septic Shock Patients (clinicaltrials.gov) - Jul 14, 2014
P=N/A, N=44, Recruiting, Sponsor: University of Roma La Sapienza
- ||| Biomarker, Immune cell: Immune Failure in Critical Therapy (INFECT) Study (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=220, Not yet recruiting, Sponsor: University of Edinburgh
- Fragmin (dalteparin sodium) / Pfizer, Eisai
Trial completion: Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot (clinicaltrials.gov) - Jul 12, 2014
P2, N=76, Completed, Sponsor: University of Manitoba
Trial primary completion date: Mar 2014 --> Mar 2015 Active, not recruiting --> Completed
- Trial primary completion date: Administration of Human Protein C Concentrates in Patients With Sepsis and Septic Shock. (clinicaltrials.gov) - Jul 10, 2014
P2, N=60, Recruiting, Sponsor: University of Roma La Sapienza
Active, not recruiting --> Completed Trial primary completion date: Nov 2011 --> Sep 2014
- Trial primary completion date: SAPS: Safety and Efficacy of Procalcitonin Guided Antibiotic Therapy in Adult Intensive Care Units (ICU's) (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=2246, Active, not recruiting, Sponsor: VU University Medical Center
Trial primary completion date: Nov 2011 --> Sep 2014 Trial primary completion date: Jul 2011 --> Aug 2014
- Enrollment closed, Trial primary completion date: SAPS: Safety and Efficacy of Procalcitonin Guided Antibiotic Therapy in Adult Intensive Care Units (ICU's) (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=2246, Active, not recruiting, Sponsor: VU University Medical Center
Trial primary completion date: Jul 2011 --> Aug 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2011 --> Aug 2014
- | Trial completion: Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Sepsis (clinicaltrials.gov) - Jul 8, 2014
P3, N=115, Completed, Sponsor: Indonesia University
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2011 --> Aug 2014 Recruiting --> Completed
- Biomarker, IO biomarker: BIONEC: Biomarkers in Patients With Flesh-eating Bacterial Infections (clinicaltrials.gov) - Jul 3, 2014
P=N/A, N=114, Recruiting, Sponsor: Ole Hyldegaard
- Clinical: Dynamic Changes of Tim-3 on Monocytes and Soluble Tim-3 in Patients With Sepsis (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=1, Recruiting, Sponsor: Chinese PLA General Hospital
- | fludrocortisone / Generic mfg., hydrocortisone / Generic mfg.
Enrollment open: APROCCHS: Activated Protein C and Corticosteroids for Human Septic Shock (clinicaltrials.gov) - Jul 1, 2014
P3, N=1280, Recruiting, Sponsor: University of Versailles
Recruiting --> Completed Suspended --> Recruiting
- Clinical: ARDS Prediction Score in Critically Ill Patients in China (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=1, Recruiting, Sponsor: Jianfeng Xie
- Review, Enrollment change: Outcomes of Severe Sepsis Patients in Surgical Intensive Care Units (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=762, Completed, Sponsor: National Taiwan University Hospital
Suspended --> Recruiting N=1100 --> 762
- Trial completion, Review, Enrollment change: Outcomes of Severe Sepsis Patients in Surgical Intensive Care Units (clinicaltrials.gov) - Jun 26, 2014
P=N/A, N=762, Completed, Sponsor: National Taiwan University Hospital
N=1100 --> 762 Recruiting --> Completed | N=1100 --> 762
- Trial primary completion date: Hyper2S: Hyperoxia and Hypertonic Saline in Septic Shock (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=441, Active, not recruiting, Sponsor: University Hospital, Angers
Recruiting --> Completed | N=1100 --> 762 Trial primary completion date: Nov 2015 --> Jun 2014
- Enrollment change: Hyper2S: Hyperoxia and Hypertonic Saline in Septic Shock (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=441, Active, not recruiting, Sponsor: University Hospital, Angers
Trial primary completion date: Nov 2015 --> Jun 2014 N=800 --> 441
- Enrollment closed, Enrollment change, Trial primary completion date: Hyper2S: Hyperoxia and Hypertonic Saline in Septic Shock (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=441, Active, not recruiting, Sponsor: University Hospital, Angers
N=800 --> 441 Recruiting --> Active, not recruiting | N=800 --> 441 | Trial primary completion date: Nov 2015 --> Jun 2014
- Enrollment change: High MAP in Septic Shock With Hypertension (clinicaltrials.gov) - Jun 18, 2014
P4, N=19, Completed, Sponsor: Southeast University, China
Recruiting --> Active, not recruiting | N=800 --> 441 | Trial primary completion date: Nov 2015 --> Jun 2014 N=24 --> 19
- Phase classification: High MAP in Septic Shock With Hypertension (clinicaltrials.gov) - Jun 18, 2014
P4, N=19, Completed, Sponsor: Southeast University, China
N=24 --> 19 Phase classification: P=N/A --> P4
- Trial completion, Phase classification, Enrollment change: High MAP in Septic Shock With Hypertension (clinicaltrials.gov) - Jun 18, 2014
P4, N=19, Completed, Sponsor: Southeast University, China
Phase classification: P=N/A --> P4 Recruiting --> Completed | Phase classification: PN/A --> P4 | N=24 --> 19
- Biomarker: Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=130, Recruiting, Sponsor: University of Florida
- Trial completion: THEMIS: Thermodilution - Controlled Management of Volume Therapy in Septic Shock (clinicaltrials.gov) - Jun 4, 2014
P=N/A, N=60, Completed, Sponsor: Claudia Spies
Recruiting --> Completed | Phase classification: PN/A --> P4 | N=24 --> 19 Recruiting --> Completed
- |||| Trial primary completion date: EUPHRATES: Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock (clinicaltrials.gov) - Jun 2, 2014
P3, N=650, Recruiting, Sponsor: Spectral Diagnostics (US) Inc.
Recruiting --> Completed Trial primary completion date: Jan 2015 --> Jul 2016
- ||||| Enrollment change: EUPHRATES: Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock (clinicaltrials.gov) - Jun 2, 2014
P3, N=650, Recruiting, Sponsor: Spectral Diagnostics (US) Inc.
Trial primary completion date: Jan 2015 --> Jul 2016 N=360 --> 650
- Trial primary completion date: TRISS: Transfusion-requirements in Septic Shock Trial (clinicaltrials.gov) - May 26, 2014
P3, N=1000, Active, not recruiting, Sponsor: Scandinavian Critical Care Trials Group
N=360 --> 650 Trial primary completion date: Dec 2013 --> Mar 2014
- Trial primary completion date: FC-Rev: Does the Time Between the End of Vascular Filling and Evaluation of Its Effectiveness Modify Fluid Challenge Results in Septic Shock? (clinicaltrials.gov) - May 21, 2014
P=N/A, N=145, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Trial primary completion date: Dec 2013 --> Mar 2014 Trial primary completion date: Mar 2016 --> May 2015
- Trial primary completion date: Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock (clinicaltrials.gov) - May 21, 2014
P=N/A, N=361, Recruiting, Sponsor: University of British Columbia
Trial primary completion date: Mar 2016 --> May 2015 Trial primary completion date: Sep 2013 --> Dec 2014
- Trial initiation date: FC-Rev: Does the Time Between the End of Vascular Filling and Evaluation of Its Effectiveness Modify Fluid Challenge Results in Septic Shock? (clinicaltrials.gov) - May 21, 2014
P=N/A, N=145, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Trial primary completion date: Sep 2013 --> Dec 2014 Initiation date: Mar 2015 --> May 2014
- Trial completion date: FC-Rev: Does the Time Between the End of Vascular Filling and Evaluation of Its Effectiveness Modify Fluid Challenge Results in Septic Shock? (clinicaltrials.gov) - May 21, 2014
P=N/A, N=145, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Initiation date: Mar 2015 --> May 2014 Trial completion date: Mar 2016 --> May 2015
- Trial completion date: Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock (clinicaltrials.gov) - May 21, 2014
P=N/A, N=361, Recruiting, Sponsor: University of British Columbia
Trial completion date: Mar 2016 --> May 2015 Trial completion date: Dec 2013 --> Feb 2015
- Enrollment open: FC-Rev: Does the Time Between the End of Vascular Filling and Evaluation of Its Effectiveness Modify Fluid Challenge Results in Septic Shock? (clinicaltrials.gov) - May 21, 2014
P=N/A, N=145, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Trial completion date: Dec 2013 --> Feb 2015 Not yet recruiting --> Recruiting
- Enrollment open: Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock (clinicaltrials.gov) - May 21, 2014
P=N/A, N=361, Recruiting, Sponsor: University of British Columbia
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- heparin sodium injection / Generic mfg.
Trial withdrawal: Safety of Heparin in Patients With Septic Shock (clinicaltrials.gov) - May 18, 2014
P2, N=0, Withdrawn, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting Recruiting --> Withdrawn
- heparin sodium injection / Generic mfg.
Enrollment change: Safety of Heparin in Patients With Septic Shock (clinicaltrials.gov) - May 18, 2014
P2, N=0, Withdrawn, Sponsor: University of Colorado, Denver
Recruiting --> Withdrawn N=100 --> 0
- || New P3 trial: Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Sepsis (clinicaltrials.gov) - May 8, 2014
P3, N=100, Recruiting, Sponsor: Indonesia University
- Trial primary completion date: The Effect of Ketanserin on the Microcirculation in Sepsis (clinicaltrials.gov) - May 7, 2014
P3, N=10, Completed, Sponsor: Medical Centre Leeuwarden
N=100 --> 0 Trial primary completion date: Mar 2014 --> May 2014
- Trial completion date: The Effect of Ketanserin on the Microcirculation in Sepsis (clinicaltrials.gov) - May 7, 2014
P3, N=10, Completed, Sponsor: Medical Centre Leeuwarden
Trial primary completion date: Mar 2014 --> May 2014 Trial completion date: Jul 2014 --> May 2014
- Trial completion: The Effect of Ketanserin on the Microcirculation in Sepsis (clinicaltrials.gov) - May 7, 2014
P3, N=10, Completed, Sponsor: Medical Centre Leeuwarden
Trial completion date: Jul 2014 --> May 2014 Recruiting --> Completed
- Trial completion, Immune cell: Mitochondrial Function of Immune Cells in Sepsis (clinicaltrials.gov) - Apr 23, 2014
P=N/A, N=60, Completed, Sponsor: University Hospital Inselspital, Berne
Recruiting --> Completed Not yet recruiting --> Completed
- || hydrocortisone / Generic mfg.
New P3 trial: Effects of Stress Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock (clinicaltrials.gov) - Apr 13, 2014
P3, N=240, Completed, Sponsor: Nanjing PLA General Hospital
- | midazolam hydrochloride / Generic mfg., dexmedetomidine / Generic mfg.
Clinical: The Effect of Dexmedetomidine on Microcirculation in Severe Sepsis (clinicaltrials.gov) - Apr 8, 2014
P4, N=60, Not yet recruiting, Sponsor: National Taiwan University Hospital
- Enrollment change: MEDUSA: Medical Education for Sepsis Source Control and Antibiotics (clinicaltrials.gov) - Mar 20, 2014
P=N/A, N=4138, Completed, Sponsor: Center for Sepsis Control and Care, Germany
Not yet recruiting --> Completed N=2000 --> 4138
- Trial completion: MEDUSA: Medical Education for Sepsis Source Control and Antibiotics (clinicaltrials.gov) - Mar 20, 2014
P=N/A, N=4138, Completed, Sponsor: Center for Sepsis Control and Care, Germany
N=2000 --> 4138 Active, not recruiting --> Completed
- Trial completion: Efficacy of Mw Vaccine in Treatment of Severe Sepsis (clinicaltrials.gov) - Mar 18, 2014
P2/3, N=50, Completed, Sponsor: Postgraduate Institute of Medical Education and Research
Active, not recruiting --> Completed Recruiting --> Completed
- New P4 trial: Effect of Different Strategies for Titrating a High MAP on Microcirculation (clinicaltrials.gov) - Mar 10, 2014
P4, N=20, Recruiting, Sponsor: Southeast University, China
- Trial termination: HYSATESS-p: Hypertonic Saline and Terlipressin for Sepsis-associated Hypotension (clinicaltrials.gov) - Mar 6, 2014
P3, N=21, Terminated, Sponsor: Hospital General de Ciudad Real
Recruiting --> Completed Recruiting --> Terminated; Low recruitment rate
- Enrollment change: HYSATESS-p: Hypertonic Saline and Terlipressin for Sepsis-associated Hypotension (clinicaltrials.gov) - Mar 6, 2014
P3, N=21, Terminated, Sponsor: Hospital General de Ciudad Real
Recruiting --> Terminated; Low recruitment rate N=42 --> 21
- | New P4 trial: CLASSIC: Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care (clinicaltrials.gov) - Mar 3, 2014
P4, N=150, Not yet recruiting, Sponsor: Anders Perner
- Enrollment closed: ADSeS: Examination of ADMA Serum Level and DDAH II (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=120, Active, not recruiting, Sponsor: Universitätsklinikum Hamburg-Eppendorf
N=42 --> 21 Recruiting --> Active, not recruiting